Karyopharm Therapeutics Inc.
As of Oct 22, 2026, Karyopharm Therapeutics is in Stage 4, the downtrend phase, now in week 10 (since Aug 17, 2026). It closed at $0.55, 94.9% below its 52-week high and below its 200-day average, which is falling.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is KPTI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
KPTI among Biotechnology517th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …517 | KPTI | Stage 4 · wk 10 | 6 | −68.8% |
Karyopharm Therapeutics: quick answers
What stage is Karyopharm Therapeutics in?
As of Oct 22, 2026, Karyopharm Therapeutics (KPTI) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 17, 2026 and is in week 10. What the four stages mean
Is Karyopharm Therapeutics in an uptrend?
No. Karyopharm Therapeutics is in a Stage 4 downtrend. It trades 91.3% below its 200-day average, which is falling.
How far is Karyopharm Therapeutics from its 52-week high?
Karyopharm Therapeutics closed at $0.55 on Oct 22, 2026, 94.9% below its 52-week high of $10.67. Its 52-week low is $0.32.
How has Karyopharm Therapeutics performed over the past year?
As of Oct 22, 2026, Karyopharm Therapeutics is down 91.5% over the past year and down 92.4% so far in 2026.
Which sector and industry is Karyopharm Therapeutics in?
Karyopharm Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.